The liposomal delivery system encapsulates the copper peptide in phospholipids to enhance absorption and bioavailability
Intended use: In vitro and preclinical in vivo laboratory research only

Common side effects (affect 10-30% of users): Growth hormone-related peptides (CJC-1295, Ipamorelin, etc.): Water retention (mild, temporary) Joint pain (usually temporary adaptation) Carpal tunnel-like symptoms (rare) Numbness/tingling in extremities (rare) Increased hunger (GHRP-6, GHRP-2) Lethargy initially (body adjusting) Healing peptides (BPC-157, TB-500): Headaches (occasional, mild) Nausea (rare) Dizziness (rare) Increased body hair growth (TB-500) Injection-related: Site reactions (redness, minor pain) Bruising (improper technique) Infection risk (if sterility not maintained) Rare but possible: Blood sugar changes (monitor if diabetic) Prolactin increase (with some GH peptides) Tachyphylaxis (reduced effectiveness over time with some peptides) What's notably absent: No testosterone suppression No cardiovascular remodeling No liver stress No hormonal disaster No PCT required No infertility issues Long-term safety: Growth hormone peptides mimic natural pulses (safer than exogenous GH) Healing peptides have excellent long-term safety profiles No evidence of organ damage with proper use Can be used for extended periods Head-to-head safety comparison Hormonal disruption: Steroids: 10/10 severity (guaranteed shutdown) Peptides: 1/10 severity (minimal hormonal impact) Cardiovascular risk: Steroids: 8/10 severity (significant risk increase) Peptides: 2/10 severity (minimal concerns) Liver toxicity: Steroids: 7/10 severity (oral steroids especially) Peptides: 0/10 severity (no liver impact) Reversibility of side effects: Steroids: 5/10 (some permanent damage possible) Peptides: 9/10 (almost everything reverses) Need for ancillary drugs: Steroids: Extensive (AI, SERM, hCG, PCT drugs, BP meds) Peptides: Minimal (maybe vitamin B6 for prolactin if needed) The safety profile of peptides is vastly superior

By 1992 Raufman and Eng had established that the lizard's saliva contained an abundance of a new peptide made up of 39 amino acids that was structurally related to GLP-1
Hoyles L, Fernndez-Real JM, Federici M, Serino M, Abbott J, Charpentier J, et al
Lloyd and Lister 2022)